X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VNRX-5022 (cefepime) & taniborbactam combination is an investigational IV beta-lactam/beta-lactamase inhibitor antibiotic, being developed for treatment of complicated urinary tract infections, including pyelonephritis & bacterial pneumonia (HABP/VABP) in adults.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: VNRX-5022
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: VenatoRx Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
The agreement aims to commercialize cefepime-taniborbactam, a beta-lactam inhibitor combination antibiotic being developed for the treatment of complicated UTI and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: VenatoRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 09, 2023
Details:
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being used for the treatment and prevention of adult patients with candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
The partnership aims to advance two antibiotics currently FDA-approved for adults, Baxdela (delafloxacin) and Vabomere (meropenem and vaborbactam), for use in pediatrics and also for the development of Baxdela against biothreat pathogens for both adults and children.
Lead Product(s): Delafloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Baxdela
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $141.9 million Upfront Cash: Undisclosed
Deal Type: Partnership July 10, 2023
Details:
Under the terms of the agreement, Xediton is responsible for the registration and commercialization of BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products in Canada.
Lead Product(s): Delafloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Baxdela
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xediton Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 15, 2023
Details:
Under the agreement, Melinta acquired exclusive rights to commercialize Rezzayo (rezafungin) in the U.S. from Cidara. Cidara recently received FDA approval for REZZAYO™, a novel, once-weekly echinocandin antifungal approved for candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Cidara Therapeutics
Deal Size: $460.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement April 24, 2023
Details:
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
CD101 (rezafungin) is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
Under the terms of the Agreement, Cidara will continue to lead the ongoing global Phase 3 ReSPECT prophylaxis study, as well as the regulatory activities for the approval of CD101 (rezafungin) in both the treatment and prophylaxis indications.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 27, 2022
Details:
TOPROL-XL®, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic, heart failure of specific origins.
Lead Product(s): Metoprolol Succinate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Toprol-XL
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: New American Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
